A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure.
Wang Z, Shi W, Wu T, Peng T, Wang X, Liu S, Yang Z, Wang J, Li PL, Tian R, Hong Y, Yang H, Bai L, Hu Y, Cheng X, Li H, Zhang XJ, She ZG.
Wang Z, et al. Among authors: wang x, wang j.
Front Cardiovasc Med. 2023 Mar 14;10:1130635. doi: 10.3389/fcvm.2023.1130635. eCollection 2023.
Front Cardiovasc Med. 2023.
PMID: 36998980
Free PMC article.